Education
About Us
Working with TipRanks
Follow Us
Anixa Biosciences Inc (ANIX)
NASDAQ:ANIX
ANIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.07 - $4.20
Previous CloseN/A
Volume56.82K
Average Volume (3M)91.46K
Market Cap
$101.74M
Enterprise Value$118.13M
Total Cash (Recent Filing)$1.05M
Total Debt (Recent Filing)$230.00K
Price to Earnings (P/E)―
Beta0.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding32,196,860
10 Day Avg. Volume56,072
30 Day Avg. Volume91,460
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)484.49
Price to Cash Flow (P/CF)-8.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.69
Forecast
1Y Price Target
$8.50Price Target Upside168.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Anixa Biosciences News
PremiumCompany Announcements
Anixa Biosciences Holds Annual Stockholder Meeting 2025
PremiumCompany Announcements
Director Shows Confidence in Anixa Biosciences with New Stock Purchase
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressAnixa Biosciences' ongoing Phase 1 trial of its CAR-T therapy in ovarian cancer has dosed the first patient in the third cohort, with no dose-limiting toxicity observed in previous cohorts.
Financial StabilityWith $17.3M in cash and a low burn rate, Anixa should have runway into FY27 and through key events generated by its partnerships to unlock investor value.
Strategic PartnershipsAnixa's strategic partnerships with leading cancer centers like Cleveland Clinic and Moffitt Cancer Center both validate its programs and ensure efficient capital use while the programs work toward generating clinical proof of concept which should pave the way to later-stage studies.
Bears Say
Clinical Trial RisksRisks include failure of the breast cancer vaccine and/or CAR-T therapy for ovarian cancer in clinical trials and failure to secure regulatory approval.
Financial PerformanceFor fiscal year 2024, net loss was $12.6M, with a cash runway of approximately 2.5 years.
---
Ownership Overview
5.29% Insiders
5.23% Mutual Funds
6.76% Other Institutional Investors
78.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANIX FAQ
What was Anixa Biosciences Inc’s price range in the past 12 months?
Anixa Biosciences Inc lowest stock price was $2.07 and its highest was $4.20 in the past 12 months.
What is Anixa Biosciences Inc’s market cap?
Anixa Biosciences Inc’s market cap is $101.74M.
When is Anixa Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Anixa Biosciences Inc’s earnings last quarter?
Anixa Biosciences Inc released its earnings results on Mar 10, 2023. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.08.
Is Anixa Biosciences Inc overvalued?
According to Wall Street analysts Anixa Biosciences Inc’s price is currently Undervalued.
Does Anixa Biosciences Inc pay dividends?
Anixa Biosciences Inc does not currently pay dividends.
What is Anixa Biosciences Inc’s EPS estimate?
Anixa Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anixa Biosciences Inc have?
Anixa Biosciences Inc has 32,196,860 shares outstanding.
What happened to Anixa Biosciences Inc’s price movement after its last earnings report?
Anixa Biosciences Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -5.797%.
Which hedge fund is a major shareholder of Anixa Biosciences Inc?
Currently, no hedge funds are holding shares in ANIX
---
Anixa Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (168.99% Upside)
$8.50 (168.99% Upside)
Insider Transactions
Bought Shares
Worth $186.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.9%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.36%
12-Months-Change
Fundamentals
Return on Equity
-58.80%
Trailing 12-Months
Asset Growth
-25.48%
Trailing 12-Months
Company Description
Anixa Biosciences Inc
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
---
ANIX Stock 12 Month Forecast
Average Price Target
$8.50
▲(168.99% Upside)
Technical Analysis
Best Analysts Covering ANIX
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-11.53%
reiterated a buy rating last month
Copying Yi Chen's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -11.53% per trade.
---